论文部分内容阅读
目的:探讨促性腺激素释放激素激动剂(Gn RH-a)对子宫内膜异位症患者血清CA125、EMAB及RANTES的影响。方法:选取我院收治的子宫内膜异位症患者92例,根据治疗方法不同分为两组,对照组予以常规治疗,治疗组在对照组基础上加用醋酸亮丙瑞林微球注射治疗。检测两组患者治疗前后血清CA125、EMAB及RANTES水平。结果:与治疗前相比,两组患者治疗后CA125、RANTES明显降低,EMAB转阴率明显升高,差异有统计学意义(P<0.05);与对照组相比,治疗组患者治疗后CA125、RANTES水平降低,EMAB转阴率升高,差异有统计学意义(P<0.05);治疗组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论:Gn RH-a能够降低子宫内膜异位症患者血清CA125、RANTES及EMAB水平,提高机体免疫功能,安全性较高,对临床具有指导意义。
Objective: To investigate the effect of GnRH-a on serum CA125, EMAB and RANTES in patients with endometriosis. Methods: Ninety-two cases of endometriosis admitted to our hospital were divided into two groups according to different treatment methods. The control group was given routine treatment. The treatment group was treated with leuprolide microsphere injection on the basis of the control group . Serum levels of CA125, EMAB and RANTES were measured before and after treatment in both groups. Results: Compared with those before treatment, the levels of CA125 and RANTES in both groups were significantly decreased and the negative rate of EMAB was significantly increased (P <0.05). Compared with the control group, the levels of CA125 and RANTES in the two groups were significantly decreased after treatment (P <0.05). The incidence of adverse reactions in the treatment group was lower than that in the control group, the difference was statistically significant (P <0.05). CONCLUSION: Gn RH-a can reduce the levels of serum CA125, RANTES and EMAB in patients with endometriosis, improve the immune function and have higher safety, which is of clinical significance.